(RTTNews) - Samsung Biologics said that it has expanded strategic manufacturing partnership with AstraZeneca (AZN.L, AZN) to include the COVID-19 and cancer therapy.
As per the deal, valued at about $380 million up from the initial $331 million for the production of drug substance and drug product, Samsung Biologics manufactures AstraZeneca's COVID-19 long-acting antibody (LAAB) combination, AZD7442, and will start to manufacture a cancer immunotherapy product from next year.
AZD7442 is a combination of two long-acting antibodys being developed for the prevention and treatment of COVID-19. AZD7442 is the first LAAB to receive an EUA from the US Food and Drug Administration (FDA) for COVID-19 prevention and it has received authorizations from the US, France, Italy, and Bahrain.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
